Loading
The National Lung Matrix Trial was the United Kingdom's umbrella trial in lung cancer: thousands of patients were screened through the NHS and those with one of 22 rare genetic changes were offered a matching drug. Most cohorts did not clear the bar, which taught the field how hard single-target matching is outside the strongest drivers.
The National Lung Matrix Trial opened in 2015, led by Gary Middleton at the University of Birmingham and fed by Cancer Research UK's Stratified Medicine Programme 2, which sequenced tumours from patients across the NHS with a 28-gene panel. Patients with one of the trial's actionable alterations and non-small-cell lung cancer that had progressed after first-line therapy entered one of 22 cohorts, each pairing a genetic change with one of eight drugs supplied by AstraZeneca and Pfizer: palbociclib, crizotinib, selumetinib with docetaxel, capivasertib, osimertinib, durvalumab, vistusertib and AZD4547. Each cohort used a Bayesian adaptive design with pre-set thresholds for response or durable benefit, so cohorts could be closed early or expanded.
The trial's main report, in Nature in 2020, covered more than 5,000 patients screened and around 300 treated across 19 cohorts. Few cohorts met their thresholds. Signals appeared where the drug matched a strong driver, and the trial confirmed the general finding of NCI-MATCH and Lung-MAP that many rarer alterations, especially loss-of-function changes and amplifications, do not predict benefit from a single targeted drug. A high proportion of screened patients could not enter because their disease had worsened or they had died before a slot opened, which quantified how slow tissue-based national screening was.
What it changed in Britain was infrastructure: it showed the NHS could run population-scale molecular screening feeding one trial, which fed directly into the design of DETERMINE and TARGET National, and it argued for combinations and for screening earlier in the disease. The trial's later cohorts, including ceralasertib with durvalumab in RAS-mutant and wild-type disease and mTORC1/2 inhibition in STK11-deficient cancers, were published in 2025 and 2026.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Bayesian estimate with 95% credible interval; posterior probability above 0.99 of exceeding the 3-month target; durable clinical benefit in 12 of 30 (40%, 25-53). Data snapshot 30 November 2019
SourceIncluding 14 re-registered for a sequential drug; 276 analysable for the primary outcomes
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Median progression-free survival, palbociclib in KRAS-mutant NSCLC (cohort C6; PFS is the primary outcome for the palbociclib arm)primary | Palbociclib, KRAS mutation without AKT activation (C6) | 30 | 5.3 months | - | - | link |
| Screening funnel | Screened | - | 5467 patients | - | - | link |
| Molecularly eligible | - | 2007 patients | ||||
| Entered the trial for genotype-matched therapy | - | 302 patients |
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Docetaxel, AstraZeneca.
Shares Master protocol (platform, basket and umbrella trials), Crizotinib, Basket, umbrella, and platform trials, Osimertinib.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Palbociclib, AstraZeneca.
Shares Seamless, adaptive and Bayesian trial designs, Master protocol (platform, basket and umbrella trials), Palbociclib, Basket, umbrella, and platform trials.
Shares Master protocol (platform, basket and umbrella trials), Basket, umbrella, and platform trials, Trial design, endpoints and cost, Comprehensive genomic profiling.
Shares Selumetinib, Docetaxel, AstraZeneca, Small-molecule kinase inhibitors.
Shares Master protocol (platform, basket and umbrella trials), Crizotinib, Palbociclib, Basket, umbrella, and platform trials.
Shares Alastair Greystoke, Sanjay Popat, Non-small-cell lung cancer.